Skip to main content
. 2010 Dec 8;50(4):740–745. doi: 10.1093/rheumatology/keq346

Table 2.

Baseline and follow-up data on SF-36 of all subjects

SF-36 Baseline Mean (s.d.) (n = 99) 1-year mean (s.d.) (n = 77) 2-year mean (s.d.) (n = 36) Effect sizea Per cent achieving MCID N (per cent) floor effect N (per cent) ceiling effect
Physical function 43.39 (11) 48.44 (8.33)* 48.73 (7.86) 0.48 34 2 (2.1) 9 (9.3)
Role physical 43.68 (11.41) 49.44 (10.41)* 50.32 (9.33) 0.50 36 3 (3.1) 18 (18.4)
Bodily pain 39.91 (11.23) 52.12 (10.77)* 52.26 (9.99) 1.09 69 6 (6.1) 6 (6.1)
General health 43.04 (8.92) 47.12 (9)* 48.83 (7.86) 0.49 38 0 (0) 1 (1.0)
Vitality 50.74 (12.24) 54.97 (11.2)* 56.37 (10.58) 0.31 41 0 (0) 7 (7.2)
Social functioning 45.5 (11.89) 51.18 (8.82)* 52.15 (7.28) 0.40 53 2 (2.0) 32 (32.7)
Role emotional 48.98 (11.04) 51.69 (8.69) 51.67 (7.4) 0.20 22 1 (1.0) 58 (58.6)
Mental health 49.73 (11.92) 52.91(10.51) 54.43 (8.75) 0.21 30 0 (0) 11 (11.3)
SF-36 PCS 40.37 (9.45) 48.48 (8.89)* 49.09 (9.15) 0.91 70 0 (0) 0 (0)
SF-36 MCS 52.16 (10.8) 54.15 (9.3) 55.11 (8.64) 0.08 38 0 (0) 0 (0)

aDifference from baseline to 1-year period. *P < 0.05; effect size = mean score1 year − mean scorebaseline.z/s.d.baseline.